Ying Yao

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Depei Wu, Jin Zhou, C. Fu, 2020, Cancer medicine.

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Depei Wu, Jin Zhou, C. Fu, 2018, Blood.

Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Depei Wu, Jin Zhou, C. Fu, 2017 .

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients

Depei Wu, H. You, Jinlan Pan, 2022, Frontiers in Oncology.

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Depei Wu, Jin Zhou, Ruju Wang, 2019, Blood.

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Juanjuan Su, Depei Wu, F. Gong, 2019, Blood.

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients

Lingzhi Yan, J. Shang, Xiaolan Shi, 2023, Frontiers in oncology.